Kolosova Natalia P, Boldyrev Nikita D, Svyatchenko Svetlana V, Danilenko Alexey V, Goncharova Natalia I, Shadrinova Kyunnei N, Danilenko Elena I, Onkhonova Galina S, Kosenko Maksim N, Antonets Maria E, Susloparov Ivan M, Ilyicheva Tatiana N, Marchenko Vasily Y, Ryzhikov Alexander B
State Research Centre of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk 630559, Russia.
Pathogens. 2023 Dec 19;13(1):1. doi: 10.3390/pathogens13010001.
In Russia, during the COVID-19 pandemic, a decrease in influenza circulation was initially observed. Influenza circulation re-emerged with the dominance of new clades of A(H3N2) viruses in 2021-2022 and A(H1N1)pdm09 viruses in 2022-2023. In this study, we aimed to characterize influenza viruses during the 2022-2023 season in Russia, as well as investigate A(H1N1)pdm09 HA-D222G/N polymorphism associated with increased disease severity. PCR testing of 780 clinical specimens showed 72.2% of them to be positive for A(H1N1)pdm09, 2.8% for A(H3N2), and 25% for influenza B viruses. The majority of A(H1N1)pdm09 viruses analyzed belonged to the newly emerged 6B.1A.5a.2a clade. The intra-sample predominance of HA-D222G/N virus variants was observed in 29% of the specimens from A(H1N1)pdm09 fatal cases. The D222N polymorphic variant was registered more frequently than D222G. All the B/Victoria viruses analyzed belonged to the V1A.3a.2 clade. Several identified A(H3N2) viruses belonged to one of the four subclades (2a.1b, 2a.3a.1, 2a.3b, 2b) within the 3C.2a1b.2a.2 group. The majority of antigenically characterized viruses bore similarities to the corresponding 2022-2023 NH vaccine strains. Only one influenza A(H1N1)pdm09 virus showed reduced inhibition by neuraminidase inhibitors. None of the influenza viruses analyzed had genetic markers of reduced susceptibility to baloxavir.
在俄罗斯,新冠疫情期间最初观察到流感传播有所减少。随着2021 - 2022年A(H3N2)病毒新分支以及2022 - 2023年A(H1N1)pdm09病毒占主导地位,流感传播再度出现。在本研究中,我们旨在对俄罗斯2022 - 2023年流感季的流感病毒进行特征描述,并调查与疾病严重程度增加相关的A(H1N1)pdm09 HA - D222G/N多态性。对780份临床标本进行的PCR检测显示,其中72.2%的标本A(H1N1)pdm09呈阳性,2.8%为A(H3N2),25%为乙型流感病毒。分析的大多数A(H1N1)pdm09病毒属于新出现的6B.1A.5a.2a分支。在29%的A(H1N1)pdm09致死病例标本中观察到HA - D222G/N病毒变体在样本内占优势。D222N多态性变体比D222G更频繁出现。所有分析的B/维多利亚病毒都属于V1A.3a.2分支。鉴定出的几种A(H3N2)病毒属于3C.2a1b.2a.2组内的四个亚分支(2a.1b、2a.3a.1、2a.3b、2b)之一。大多数经抗原特性鉴定的病毒与相应的2022 - 2023年北半球流感疫苗株相似。只有一株甲型流感A(H1N1)pdm09病毒对神经氨酸酶抑制剂的抑制作用降低。分析的流感病毒均无对巴洛沙韦敏感性降低的基因标记。